ADVANCED HIV DISEASE – DIAGNOSIS, TREATMENT AND MANAGEMENT

Stephen N. Symes MD, FACP

Department of Medicine

Division of Infectious Diseases and Clinical Immunology

OBJECTIVES

- Diagnosis of Advanced HIV Disease in Adults – including outlining the concept of Packaged care
- Initial Management – treat the underlying issues – and what Antiretroviral Therapy and When to use?
- Recognition of Special Opportunistic conditions – Cryptococcal Disease, Histoplasmosis, Tuberculosis and Kaposi's Sarcoma.
- Special Considerations – from IRIS to Treatment failure

https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/treatment/advanced-hiv-disease

WHO CLASSIFICATION FOR HIV PROGRESSION
Based on Clinical Staging

Stage 1 Asymptomatic	Stage 2 Mild disease	Stage 3 Moderate disease	Stage 4 Severe disease (AIDS)
No symptoms	Wt. loss>5–10%	Wt. loss>10%	HIV wasting syndrome
	Sore or cracks around the lip	Oral thrush	Esophageal thrush
Or only persistent generalized lymphadenopathy	Seborrhea	Oral hairy	More than 1 month: Herpes simplex ulceration
	Prurigo	Leukoplakia	Lymphoma
	Herpes zoster	More than 1 month	Kaposi sarcoma
	Recurrent URTI	• Diarrhea	Invasive cervicalcancer
	Recurrent mouth ulcer	• Unexplained fever	Pneumocystic pneumonia
		• Severe bacterial infection	Extrapulmonary TB
		• Pneumonia	Cryptococcal meningitis
		• Muscle infection	Toxoplasma brain abscess
		Pulmonary TB	Visceral leishmaniasis
		TB lymphadenopathy	HIV encephalopathy
		Acute necrotizing ulcerative gingivitis	

HIV: Human immunodeficiency virus, AIDS: Acquired immunodeficiency syndrome

The WHO clinical staging of HIV/AIDS cases

Daakeek, Ahmed & Bahashwan, Abdulrahim. (2019). People Living with Human Immunodeficiency Virus in Hadhramout: Clinical Presentation and Outcomes. Journal of Pathology and Infectious Diseases. 2. 10.33309/2639-8893.020103.

Table 1. CDC Case Definition for HIV Infection Stage Among Adolescents and Adults

Stage	CD4 Cell Count	CD4%*	Clinical Evidence<
Stage 0	Early HIV infection		
Stage 1	>500 cells/mm^3	≥26%	No AIDS-Defining Condition
Stage 2	200-499 cells/mm^3	14-25%	No AIDS-Defining Condition
Stage 3	<200 cells/mm^3	<14%	*or* Documentation of AIDS-Defining Condition
Unknown	No data	No data	*and* No information on AIDS-Defining Condition

*Use CD4 percentage only if no data available for CD4 count

Source: Centers for Disease Control and Prevention. Revised surveillance case definition for HIV infection--United States, 2014. MMWR Recomm Rep. 2014;63:1-10. [**PubMed Abstract**]

WHO CLASSIFICATION FOR HIV PROGRESSION

Advanced HIV disease	For adults, adolescents and children five years and older, advanced HIV disease is defined as a CD4 cell count ≤200 cells/mm³.[a] At presentation, all children living with HIV younger than five years should be considered as having advanced HIV disease unless they have received ART for more than a year and are clinically stable.

A 35-year-old woman comes to the Emergency Department

Fever, odynophagia and weight loss, 10 lbs over 2 weeks.

HIV test was negative 1 year ago, but current rapid test is positive.

She fails to respond to oral or iv fluconazole 200mg.

Endoscopy = 2 deep ulcerations, negative for CMV, HSV, Fungus, malignancy.

CD4 = 340 (16%) and vl= 1.4 million copies/ml

Does she have AIDS?

Does she have Advanced HIV Disease?

How would you treat?

HIV PATHOGENESIS

- HIV attacks T cells
- T-cells a critical part of the immune/defense system
- Disables the T-cells, which become virus "factories"
- Less T-cells and more and more virus, as time goes on…..





"USUAL" COURSE OF HIV INFECTION IN ADULTS



https://en.wikipedia.org/wiki/HIV/AIDS#/media/File:Hiv-timecourse.png

The Variable Course of HIV-1 Infection



Reprinted with permission from Haynes. In: DeVita et al, eds. *AIDS: Etiology, Treatment and Prevention.* 4th ed. Lippincott-Raven Publishers; 1997:89-99.



Figure 1. Elite Controller



Figure 2. Viremic Controller





OUR CASE

- 35-year-old woman
- Fever, odynophagia, weight loss
- HIV test was negative 1 year ago, but current rapid test is positive.
- Fails to respond to iv fluconazole, can't swallow
- Endoscopy = deep ulcer, negative for CMV, HSV, Fungus, malignancy.
- CD4 = 340 (16%) and vl= 1.4 million copies/ml
- Does she have AIDS?
- Does she have Advanced HIV Disease?
- How would you treat?

2014 CDC Revised Classification System: Stage 3-Defining Opportunistic Illnesses in HIV Infection

- Bacterial infections, multiple or recurrent*
- Candidiasis of bronchia, trachea, or lungs
- Candidiasis of esophagus
- Cervical cancer, invasive+
- Coccidioidomycosis, disseminated or extrapulmonary
- Cryptococcosis, extrapulmonary
- Cryptosporidiosis, chronic intestinal (>1 month)
- Cytomegalovirus disease (other than liver, spleen, or nodes), onset age > 1 month
- Cytomegalovirus retinitis (with loss of vision)
- Encephalopathy attributed to HIV^
- Herpes simplex: chronic ulcers (present for >1 month) or bronchitis, pneumonitis, or esophagitis (onset at age > 1 month)
- Histoplasmosis, disseminated or extrapulmonary
- Isosporiasis, chronic intestinal (> 1 month's duration)
- Kaposi's sarcoma
- Lymphoma, Burkitt's (or equivalent term)
- Lymphoma, immunoblastic (or equivalent term)
- Lymphoma, primary of brain
- *Mycobacterium avium* complex or *Mycobacterium kansasii*, disseminated or extrapulmonary
- *Mycobacterium tuberculosis* of any site, pulmonary+, disseminated, or extrapulmonary
- *Mycobacterium*, other species or unidentified species, disseminated or extrapulmonary
- *Pneumocystis jirovecii* (previously known as "*Pneumocystis carinii*") pneumonia
- Pneumonia, recurrent+
- Progressive multifocal leukoencephalopathy
- Salmonella septicemia, recurrent
- Toxoplasmosis of brain, onset at age > 1 month
- Wasting syndrome attributed to HIV

*Only among children aged < 6 years
+Only among adults, adolescents, and children aged ≥ 6 years
^Suggested diagnostic criteria for these illnesses are defined in prior surveillance case definitions

Recommendations

CD4 testing is recommended as the preferred method to identify advanced HIV disease in people living with HIV. (New, 2025)
Strong recommendation, moderate certainty evidence.

In settings where CD4 testing is not yet available, WHO clinical staging can be used to identify advanced HIV disease in people living with HIV. (New, 2025)
Conditional recommendation, very low certainty evidence.

A package of interventions including screening, treatment and/or prophylaxis for major opportunistic infections, rapid ART initiation and intensified adherence support interventions should be offered to everyone presenting with advanced HIV disease. (2017)
Strong recommendation, moderate-certainty evidence

WHEN TO START ART IN HIV PATIENTS (INCLUDING HOSPITALIZED?)

ART is recommended for all HIV – infected individuals

Limits are related to education (including provider knowledge), pill burden, funding and regulatory issues

Absolute indication for patients for which there is no effective therapy

Cryptosporidiosis, microsporidiosis, PML, AIDS Dementia

Relative = KS, Lymphoma, whitlow

<u>IRIS – Immune Response Inflammatory Syndrome</u>

Strong Response of recovering Immune System to Latent or Active Infection

Table 4. Summary of timing of ART for individuals with opportunistic infections and comorbid conditions *(8, 58, 82, 83)*

Clinical status of people living with HIV	Timing of ART initiation
No signs and symptoms of TB	Rapid ART initiation, including starting ART on the same day that a diagnosis is confirmed should be offered to all people living with HIV following clinical assessment.
Suspected TB	Rapid ART initiation should be offered to all people living with HIV following a confirmed HIV diagnosis and clinical assessment and to people living with HIV with signs and symptoms suggesting TB. Except for central nervous system disease (meningitis), initiate ART while rapidly investigating for TB, with close follow-up within seven days to initiate TB treatment if TB is confirmed.
TB disease	ART should be started as soon as possible within two weeks of initiating TB treatment, regardless of CD4 cell count, among people living with HIV (except for tuberculous meningitis and multidrug-resistant TB)
Diagnosed with TB meningitis	ART should be delayed at least four weeks (and initiated within eight weeks) after treatment for TB meningitis is initiated. Corticosteroids should be considered adjuvant treatment for TB meningitis, but cryptococcal meningitis should be ruled out since steroid use can lead to more adverse events.
Cryptococcal meningitis	ART initiation should be deferred by 4–6 weeks from the initiation of antifungal treatment.
Histoplasmosis	ART should be initiated as soon as possible among people with disseminated histoplasmosis for whom central nervous system involvement is not suspected or proven.
Kaposi's sarcoma	ART should be rapidly initiated alongside management of Kaposi's sarcoma.


Risk factors:
Low CD4 count
Disseminated OI
Paucity of inflammatory response to OI (in CM)
Short duration or suboptimal OI treatment
ART initiation
High antigen load
Immune cell dysfunction
Innate immune responses
Acquired immune responses
Excess proinflammatory cytokine activity
Possible mechanisms:
Uncoupling of innate and acquired immunity
Restoration of exuberant pathogen-specific cellular immune responses
Defective or delayed regulatory responses
Signs: focal
Localised tissue edema and focal inflammation
Symptoms of IRIS
Signs: systemic
Systemic inflammatory response







Paradoxical IRIS:

Differential diagnosis:

1) ART/OI treatment toxicity

2) OI drug resistance

3) Poor adherence to treatment

4) Other new OI

ART-associated OI (possible scenarios):

1) Unmasking IRIS

or

2) Missed OI diagnosis at presentation with clinical progression and presentation that is not unusual

or

3) New OI due to persisting immune deficiency

https://www.dovepress.com/cr_data/article_fulltext/s42000/42328/img/fig1.jpg

Year of publication	Recommendations
Interventions to provide at hospital discharge	
New, 2025	Hospitalized people with HIV may be provided interventions to support transitions to outpatient care and reduce avoidable readmissions. *(Conditional recommendation, low-certainty evidence)* Interventions may include: • pre-discharge goal setting • medication review • transitional care planning • telephone follow-up • home visits by health-care providers and/or peer supporters • individualized support.

PACKAGING

INITIAL PRIMARY CARE LABORATORY EVALUATION

General	HIV Specific
CBC w/diff	CD4 Count
Creatinine, glucose, LFT's, Lipid profile	HIV RNA Assay (Viral load)
Serologies: Toxo, CMV, Varicela IgG, Hep A,B,C and RPR	HIV- resistance (genotype)
Tb Screen: PPD or IGRA	HLA B*5701
PAP smear: cervical and/or anal, GC and Chlamydia	Crytococcal Ag, maybe Histo Ag

COMPONENTS OF THE WHO-RECOMMENDED ADVANCED HIV DISEASE PACKAGE OF CARE

- **SCREENING**
  - Tuberculosis
  - Cryptococcal Disease
  - Nutritional deficits
- **DIAGNOSIS**
- **PROPHYLAXIS AND TREATMENT**
- **ANTIRETROVIRAL THERAPY**
- **COUNSELLING**
  - Adherence
  - Mental Health
  - Nutrition

OUR CASE



35-year-old woman

Fever, odynophagia, weight loss

Acute Retroviral Syndrome, or Rapid Progressor

Idiopathic Esophageal Ulcer.



CD4 = 340 (16%) and vl= 1.4 million copies/ml on Biktarvy

Does she need PJP/ Cryptococcal prophylaxis?

What virological response is expected?

AFTER STARTING ART FOR PATIENT WITH HIV

Which of the following is TRUE:

A. The CD4 cell count is the most important test to obtain at 1 month after starting therapy.

B. A follow-up HIV RNA value should first be checked 10-12 weeks after starting therapy.

C. A follow-up HIV RNA value should first be checked 2-4 weeks after starting therapy.

D. A decrease in HIV RNA from 1.4 million copies/ml to 500,000 copies/ml after 4 weeks indicates an excellent early response





RESPONSE TO ART

- VL is a measure of "how much" virus..
  - ND = not detected (<20 or <50)
  - Low = <5000 copies/ml
  - Intermediate = 5K -50,000
  - High = > 50,000
- Treatment
  - Effective treatment reduces levels > 1 log in 2-4 weeks
  - ND does NOT mean "Not there"



Figure 18. Median CD4 Cell Count Over Time After Starting Antiretroviral Therapy

J Acquir Immune Defic Syndr. 2007;45:183-92.

PROPHYLAXIS

- 2018, WHO guidelines - all adults and adolescents w/ CD4 cell count <100 cells/mm3 be screened for cryptococcal antigen before ART initiation or reinitiation; consider for CD4 cell count <200 cells/mm3.
- fluconazole primary prophylaxis may be considered at a higher CD4 cell count threshold of <200 cells/mm3
- WHO does not currently recommend routine screening for Histoplasmosis
- Molecular WHO-recommended rapid diagnostic tests used to screen for TB disease
- WHO recommendations for using co-trimoxazole as prophylaxis,

  based on moderate-certainty evidence

  reduces the mortality with CD4 count <350 cells/mm3 or stage 3 or 4 AIDS-defining illness



Recommendation 2025

In adults and adolescents with HIV eligible for tuberculosis preventive treatment (TPT), three months of weekly isoniazid + rifapentine (3HP) is the suggested preferred regimen; six or nine months of daily isoniazid (6H or 9H) are alternative regimens.*

conditional recommendation, low certainty of evidence

*considering and complementing existing recommendations on TPT regardless of HIV status (1)

Recommendation for treatment of Kaposi's sarcoma (new, 2025)

WHO suggests paclitaxel or pegylated liposomal doxorubicin for pharmacological treatment for people living with HIV with Kaposi's sarcoma. *(Conditional recommendation, low-certainty evidence)*

Recommendation for treatment of mild or moderate Kaposi's sarcoma *(83)* (2014)

In HIV-infected adults, adolescents and children diagnosed with mild or moderate Kaposi sarcoma, immediate ART initiation is recommended. *(Strong recommendation, low-certainty evidence)*

Recommendation for treatment of severe or symptomatic Kaposi's sarcoma *(83)* (2014)

Severe or symptomatic disease: in HIV-infected adults, adolescents and children diagnosed with severe symptomatic Kaposi sarcoma, immediate ART initiation in combination with systemic chemotherapy is recommended. *(Strong recommendation, low-certainty evidence)*







HIV-1 Lifecycle



Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy	
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza	
Dolutegravir-Abacavir-Lamivudine Triumeq	
Dolutegravir-Lamivudine Dovato	
Dolutegravir-Rilpivirine Juluca	
Doravirine-Tenofovir DF-Lamivudine Delstrigo	
Efavirenz-Tenofovir DF-Emtricitabine Atripla	

COMBINATION THERAPY FOR HIV: 1997 VS. TODAY

8 SINGLE PILL COMBO'S AVAILABLE AND ONE INJECTABLE

Table 1. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

Panel's Recommendations for Initiating Antiretroviral Therapy in Treatment-Naive Patients

- Antiretroviral therapy (ART) is recommended for all individuals with HIV to reduce morbidity and mortality (**AI**) and to prevent the transmission of HIV to others (**AI**).
- Initiate ART immediately (or as soon as possible) after HIV diagnosis in order to increase the uptake of ART and linkage to care, decrease the time to viral suppression for individual patients, and improve the rate of virologic suppression among persons with HIV (**AII**).
- When initiating ART, it is important to educate patients regarding the benefits of ART and to deploy strategies to optimize care engagement and treatment adherence (**AIII**).

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = Data from randomized controlled trials; II = Data from well-designed nonrandomized trials or observational cohort studies with long-term clinical outcomes; III = Expert opinion

Source: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Initiation of antiretroviral therapy. December 18, 2019. [HIV.gov]

Table 2. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

Recommended Initial Regimens for Most People with HIV

Recommended regimens are those with demonstrated durable virologic efficacy, favorable tolerability and toxicity profiles, and ease of use. Choice of antiretroviral therapy during pregnancy should be guided by recommendations from the Perinatal Guidelines.

For people who do NOT have a history of long-acting cabotegravir use as HIV PrEP, the following regimens are recommended:

INSTI + 2 NRTIs:

- Bictegravir-tenofovir alafenamide-emtricitabine (**AI**)
- Dolutegravir plus (tenofovir alafenamide or tenofovir DF)[a] plus (emtricitabine or lamivudine) (**AI**)

INSTI + 1 NRTI

- Dolutegravir-lamivudine (**AI**)—except for individuals with HIV RNA >500,000 copies/mL, HBV coinfection, or when antiretroviral therapy is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available

For people with HIV and a history of using long-acting cabotegravir as HIV PrEP, integrase genotypic drug resistance testing should be done before the start of antiretroviral therapy. If treatment is begun prior to the results of genotypic testing, the following regimen is recommended:

Boosted PI + 2 NRTIs:

- Darunavir (boosted with cobicistat or ritonavir) plus (tenofovir alafenamide or tenofovir DF)[a] plus (emtricitabine or lamivudine)—pending the results of the genotype test (**AIII**).

A 26-year-old man has a new clinic visit to establish care for HIV and start antiretroviral therapy. About 14 months ago, he started receiving long-acting injectable cabotegravir for HIV preexposure prophylaxis (PrEP). He stopped taking the injectable cabotegravir about 4 months ago and did not have any follow-up visits until a recent visit 3 days ago when he tested positive for HIV. The HIV genotypic drug resistance testing (standard resistance assay and integrase resistance assay) is pending.

According to the Adult and Adolescent ART Guidelines, which one of the following regimens would be recommended as initial therapy for this man?

- Dolutegravir-abacavir-lamivudine
- Bictegravir-tenofovir alafenamide-emtricitabine
- Darunavir-cobicistat-tenofovir alafenamide-emtricitabine
- Atazanavir plus ritonavir plus tenofovir DF-emtricitabine

A 26-year-old man was diagnosed with HIV 7 weeks prior. His initial laboratory studies showed an HIV RNA level of 108,656 copies/mL, a CD4 count 342 cells/mm^3, positive hepatitis B surface antibody (HBsAb), and negative hepatitis B surface antigen (HBsAg). He missed his initial follow-up appointment to start antiretroviral therapy. Results from an HIV drug resistance genotype test are now available and show no resistance mutations. He has never taken HIV preexposure prophylaxis (PrEP).

Is this man a candidate to receive 2-drug therapy with dolutegravir-lamivudine?

- No, because the baseline HIV RNA level is greater than 100,000 copies/mL
- No, because the baseline CD4 count is less than 350 cells/mm^3
- No, because he has a positive hepatitis B surface antibody test
- Yes, if using dolutegravir-lamivudine as the 2-drug regimen

Several antiretroviral regimens are found to be effective and tolerable as initial regimens but have some disadvantages or have fewer supporting data from randomized clinical trials compared with the recommended regimens. However, one of these regimens may be preferred for an individual with HIV in certain clinical situations.

INSTIs + 2 NRTIs:

- Dolutegravir-abacavir-lamivudine (**BI**)—if **HLA-B*5701 negative and without chronic HBV coinfection**

Boosted PI plus 2 NRTIs:

- Darunavir-cobicistat[a] plus (tenofovir alafenamide or tenofovir DF)[b] plus (emtricitabine or lamivudine) (**BI**)
- Darunavir plus ritonavir plus (tenofovir alafenamide or tenofovir DF)[b] plus (emtricitabine or lamivudine) (**BI**)
- Darunavir-cobicistat[a] plus abacavir-lamivudine—**if HLA-B*5701 negative** (**BII**)
- Darunavir plus ritonavir plus abacavir-lamivudine—**if HLA-B*5701 negative** (**BII**)

NNRTI + 2 NRTIs:

- Doravirine-tenofovir DF[b]-lamivudine (**BI**)
- Doravirine plus tenofovir alafenamide[b]-emtricitabine (**BIII**)
- Rilpivirine-tenofovir alafenamide[b]-emtricitabine (**BII**)—**if HIV RNA <100,000 copies/mL and CD4 count >200 cells/mm^3**

A 55-year-old woman was recently diagnosed with HIV, with an initial CD4 count of 349 cells/mm^3 and an HIV RNA level of 158,780 copies/mL. She is now being seen in clinic 4 weeks later and the plan is to start antiretroviral therapy. There is no evidence of resistance on the baseline genotype resistance assay. You are considering using either tenofovir DF-emtricitabine, tenofovir alafenamide-emtricitabine, or abacavir-lamivudine as the nucleoside reverse transcriptase inhibitor (NRTI) backbone, in combination with a third anchor drug.

Which one of the following is TRUE regarding the NRTI backbone options for this patient as part of the initial antiretroviral therapy regimen?

- Abacavir-lamivudine gives better rates of virologic suppression than tenofovir DF-emtricitabine, regardless of the baseline HIV RNA or the anchor drug used in the regimen
- Abacavir requires baseline HLA-B*5701 screening and abacavir should not be used in persons with a positive test
- Tenofovir alafenamide is more likely than tenofovir DF to cause bone mineral density problems
- Baseline testing for fractional excretion of phosphorus is recommended prior to using tenofovir DF or tenofovir alafenamide

METABOLIC COMPLICATIONS OF ART

- Peripheral Neuropathy
- Insulin Resistance (diabetes)
- Cardiac Risk
- Osteoporosis
- Renal insufficiency
- Lipid abnormalities
- Lipoatrophy and Lipodystrophy



http://www.psychiatrictimes.com/sites/default/files/aidsreader/1294813.png

Figure 4. Cardiovascular Risk in Persons with HIV

4A 4B



Figure 4A. Kaiser Observational Study (1996-2001): Coronary Heart Disease Hospitalization and Myocardial Infarction

Source: Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-7.

CENTRAL ILLUSTRATION: HIV and Ischemic Heart Disease: Etiopathogenesis of HIV-Associated Coronary Artery Disease



Vachiat, A. et al. J Am Coll Cardiol. 2017;69(1):73-82.

Ahmed

Haitian Patient, before and after Receiving Free Treatment for HIV Infection and Tuberculosis....March 2003 to Sept 2003



Kim J and Farmer P. N Engl J Med 2006;355:645-647

The NEW ENGLAND JOURNAL of MEDICINE

A 40-year-old woman with HIV presents to clinic for a follow-up visit. She has taken antiretroviral therapy for 3 years and has experienced a CD4 count increase from 168 to 380 cells/mm^3. In addition, she has maintained undetectable HIV RNA levels for more than 18 months. She complains of mild side effects from the medications, but does not miss any doses. She is going to be traveling for about 6 months and wants to take a drug holiday during this 6-month period.

Which one of the following is TRUE regarding antiretroviral treatment interruption in this patient?

- Since the CD4 count is greater than 350 cells/mm^3, a treatment interruption is indicated
- Since the HIV RNA levels have been undetectable for longer than 2 years, a treatment interruption is indicated
- Indications for treatment interruption in persons with HIV include hemoglobin less than 12 g/dL, platelet count less than 50,000/µL, or albumin less than 3 g/dL
- Planned treatment interruption is not recommended

A 37-year-old man was diagnosed with HIV 4 years prior with a CD4 count of 852 cells/mm^3 and an undetectable HIV RNA. The HIV RNA level was repeated multiple times over the following 6 months and was consistently undetectable. Based on these findings, he was considered an "elite controller." During the prior 3 months, the HIV RNA levels remained undetectable, but the CD4 count declined, with a recent CD4 count of 486 cells/mm^3. He has never taken antiretroviral therapy.

Which one of the following should be recommended at this point?

- Continue without antiretroviral therapy unless the CD4 count decreases to less than 350 cells/mm^3
- Continue without antiretroviral therapy unless the HIV RNA level increases to a level greater than 1,000 copies/mL
- Start dolutegravir plus tenofovir alafenamide-emtricitabine
- Start tenofovir alafenamide-emtricitabine

SUMMARY SLIDE 1

- Diagnosis of Advanced HIV Disease in Adults can be clinical staging or low CD4 <200
- Initial Management – treat the underlying issue – and start targeted ART as soon as possible
- Structured discharge planning to optimize transition to outpatient care
- Use WHO Package of Care to Guide screening, Diagnosis, Prohylaxis for OI's, ART and counselling
- Recognition of Special Opportunistic conditions – Cryptococcal Disease, Histoplasmosis, Tuberculosis and Kaposi's Sarcoma that increase morbidity
- Special Considerations – from IRIS to Treatment Failure

SUMMARY SLIDE 2

- Six classes of antiretroviral medications, which target HIV life cycle, have been developed for clinical use: (1) entry inhibitors, (2) NRTIs, (3) NNRTIs, (4) INSTIs, (5) PIs, and (6) capsid inhibitors.
- Guidelines recommend initiation of antiretroviral therapy for all persons with HIV to reduce disease progression and prevent transmission.
- *Recommended Initial Regimens for Most People with HIV*, in the absence of a history of long-acting cabotegravir for HIV PrEP, consists of an INSTI anchor drug (Bictegravir or dolutegravir) plus a 2-drug NRTI backbone.
- If a person is diagnosed with HIV while or after receiving long-acting cabotegravir for PrEP, an integrase genotype should be performed prior to initiating INSTI-based antiretroviral therapy. If antiretroviral therapy is initiated prior to integrase genotype results, a boosted darunavir-based regimen should be prescribed.

SUMMARY SLIDE 3

- The choice of the initial antiretroviral regimen depends on multiple patient factors, including medical and mental health comorbidities, patient preferences, insurance coverage, drug interactions, and prior HIV PrEP usage.
- After the initiation of antiretroviral therapy, laboratory monitoring is important to determine the HIV RNA response to therapy, evaluate the CD4 count response, and to monitor for antiretroviral toxicity.
- Virologic response to antiretroviral therapy is the most important factor in predicting an overall successful treatment outcome, and most patients will achieve virologic within 12 to 16 weeks.
- Typically, a brisk increase in CD4 cells in the first 3 to 6 months after starting antiretroviral therapy, followed by a more gradual increase over 3 to 6 years, although a small proportion of patients fail to recover their CD4 count at a level greater than 200 cells/mm^3 despite sustained virologic suppression.
- Scheduled antiretroviral treatment interruption is not recommended since this practice has been linked to an increased risk of opportunistic infection and death.